Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8105807 | 0.98 | PIK3CD (0.42) | PIK3CDKDRPIK3CAKITPDGFRA | |
| SCHEMBL8097227 | 0.96 | PIK3CD (0.43) | PIK3CDKDRPIK3CAKITPDGFRA | |
| SCHEMBL8097252 | 0.89 | CA12 (0.43) | PIK3CDPIK3CAEPHX2 | |
| SCHEMBL8088889 | 0.88 | PIK3CD (0.44) | PIK3CDKDRPIK3CAKITNAMPT | |
| SCHEMBL8099845 | 0.88 | KDR (0.41) | PIK3CDKDRPIK3CAKITPDGFRA | |
| SCHEMBL8092989 | 0.88 | PIK3CA (0.46) | PIK3CDPIK3CA | |
| SCHEMBL8091781 | 0.87 | CA12 (0.43) | PIK3CDPIK3CAEPHX2 | |
| SCHEMBL8097556 | 0.86 | PIK3CA (0.42) | PIK3CDPIK3CA | |
| SCHEMBL8090572 | 0.86 | PIK3CD (0.41) | PIK3CDKDRPIK3CAKITPDGFRA | |
| SCHEMBL8083631 | 0.86 | PIK3CD (0.41) | PIK3CDKDRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |